© 2002 by Heart
EDITORIAL
Are angiotensin II receptor blockers indicated in chronic heart failure?
Correspondence to:
Correspondence to:
Professor Michel Komajda, Service de Cardiologie, Hôpital Pitié-Salpétrière, 47-83 Boulevard de l'hôpital, 75651 Paris Cedex 13, France;
michel.komajda@psl.ap-hop-paris.fr
Have the theoretical advantages of the angiotensin II receptor blockers become reality for the treatment of chronic heart failure?
Keywords: angiotensin coverting enzyme inhibitor; angiotensin II receptor blocker; heart failure
Abbreviations: ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CHARM, candesarton in heart failure—assessment of reduction in mortality and morbidity; ELITE, evaluation of losartan in the elderly; NYHA, New York Heart Association; OPTIMAAL, optimal trial in myocardial infarction with the angiotensin II antagonist losartan; RENAAL, reduction of end points in NIDDM with the angiotensin II antagonist losartan; VALIANT, valsartan in acute myocardial infarction trial; Val-HeFT, valsartan heart failure trial
Chronic heart failure is one of the most serious cardiac problems encountered in clinical practice. Modulation of the renin angiotensin system is a key element in the treatment of this syndrome. There is overwhelming evidence in favour of the benefit of angiotensin converting enzyme (ACE) inhibitors on morbidity and mortality in mild to severe heart failure and in heart failure or left ventricular dysfunction following acute myocardial infarction.1 It is not known, however, whether the benefit of ACE inhibition is solely attributable to blockade of angiotensin II production or also related to bradykinin accumulation.2 Moreover, bradykinin accumulation has been implicated in the adverse effects observed with ACE inhibitors such a cough and might result in prejunctional noradrenaline (norepinephrine) release.3
The development of orally active, non-peptide angiotensin II type I receptor blockers (ARBs) has raised hopes for a new generation of modulators of the renin angiotensin system better tolerated and potentially
Relevant Articles
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
Heart 2002 87: 345.
Heart 2002 87: 280.
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
-
Drugs: cardiovascular system
-
Epidemiology
-
Acute coronary syndromes
-
Hypertension
-
Diabetes
- Relevant Articles
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
